MPM-backed Were­wolf, Mer­ck-part­nered Arti­va make quick IPO flip while Lu­ca Santarel­li's biotech rais­es $127.5M

The jump from crossover rounds to biotech IPO is quick­er than ever.

Just weeks af­ter un­veil­ing Se­ries B rounds, MPM-backed Were­wolf and Mer­ck-part­nered Arti­va are spelling out plans to go pub­lic on Nas­daq. Both have pen­ciled in the stan­dard goal of rais­ing $100 mil­lion.

That fig­ure is fast be­com­ing an un­re­li­able place­hold­er, as many com­pa­nies have gone on to raise a lot more. Lu­ca Santarel­li’s Swiss rare dis­ease play­er Vec­tivBio, though, stuck close to the range, bag­ging $127.5 mil­lion from its Nas­daq de­but.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER